Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3291 in Active Ulcerative Colitis
NCT01612039Phase 2Completed
- Sponsor
- Telsar Pharma, Inc.
- Start
- Jul 2012
- Primary completion
- Apr 2014
- Modality
- Cyclic Peptides
01
Overview
A Phase 2 trial of ASP3291 in ulcerative colitis (UC), sponsored by Telsar Pharma, Inc.. Started Jul 2012; status: completed.
02
Drugs
ASP3291
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01612039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01612039.